In patients with type II hyperlipidemia or CAD, a 16 to 26% increase in HDL-C plasma levels was achieved by a CETP inhibitor or niacin, and was associated with improved endothelial function, but only in the subgroup of patients with low baseline HDL-C levels [40], [41]. The gene discussed is CETP; the disease is familial hypercholesterolemia.